Asthma is a heterogeneous chronic inflammatory disorder of the airways with a complex etiology, which involves a variety of cells and cellular components. Therefore, the aim of the study was to investigate the effects and mechanisms of antagonistic peptides that specifically bind to the first and second extracellular loops of CCR5 (GH and HY peptides, respectively) and anti-interleukin-23 subunit p19 (anti-IL-23p19) in the airway and thereby mediate inflammation and the IL-23/T helper 17 (Th17) cell pathway in asthmatic mice. An experimental asthma model using BALB/c mice was induced by ovalbumin (OVA) and treated with peptides that are antagonistic to CCR5 or with anti-IL-23p19. The extents of the asthmatic inflammation and mucus production were assessed. In addition, bronchoalveolar lavage fluid (BALF) was collected, the cells were counted, and the IL-4 level was detected by ELISA. The IL-23/Th17 pathway-related protein and mRNA levels in the lung tissues were measured, and the positive production rates of Th17 cells in the thymus, spleen, and peripheral blood were detected. The groups treated with one of the two peptides and/or anti-IL-23p19 showed significant reductions in allergic inflammation and mucus secretion; decreased expression levels of IL-23p19, IL-23R, IL-17A and lactoferrin (LTF); and reduced proportions of Th17 cells in the thymus, spleen, and peripheral blood. Specifically, among the four treatment groups, the anti-IL-23p19 with HY peptide group exhibited the lowest positive production rate of Th17 cells. Our data also showed a significant and positive correlation between CCR5 and IL-23p19 protein expression. These findings suggest that the administration of peptides antagonistic to CCR5 and/or anti-IL-23p19 can reduce airway inflammation in asthmatic mice, most likely through inhibition of the IL-23/Th17 signaling pathway, and the HY peptide can alleviate inflammation not only through the IL-23/Th17 pathway but also through other mechanisms that result in the regulation of inflammation.
1 January 2021 in Allergy, Asthma & Immunology Research
This study aimed to develop and validate a bedside risk analysis system for predicting the clinical severity and prognosis of patients with COVID-19. A total of 444 COVID-19 patients were included and were randomly assigned into two groups at a ratio of 2:1 as derivation and validation groups. The new scoring system comprised of eight variables, which included history of having malignant diseases, history of having diabetes mellitus, dyspnea, respiratory rate of >24 bpm, C-reactive protein (CRP) of >14 mg/L, white blood cell count of >8×109/L, platelets count of <180×1012/L, and lymphocyte count of <1×109/L. The sensitivity analysis revealed that this new score performed better than the sequential organ failure assessment (SOFA) score at the first day of admission. The receiver characteristic curve analysis revealed that this score predicted severe cases of COVID-19 infection at 0.831 (95% confidence interval: 0.783-0.879) and 0.798 (95% confidence interval: 0.727-0.869) of the area under the curve in the derivation and validation group. The proposed risk score system is a fairly reliable and robust tool for evaluating the severity and prognosis of patients with COVID-19. This may help to early identify severe patients with poor prognosis, who may require more intense interventions.